{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:38:37Z","timestamp":1792597117159,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ecl.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:48:50Z","timestamp":1788551330000},"page":"617-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hormone Therapy Considerations for Breast Cancer Survivors and High-Risk Women"],"prefix":"10.1016","volume":"55","author":[{"given":"Kathryne","family":"Sanserino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10430","key":"10.1016\/j.ecl.2026.07.002_bib1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0140-6736(23)02802-7","article-title":"Managing menopause after cancer","volume":"403","author":"Hickey","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2026.07.002_bib2","article-title":"Menopausal hormone therapy for breast cancer patients: what is the current evidence?","author":"Glynne","year":"2024","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.ecl.2026.07.002_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.6004\/jnccn.2025.0028","article-title":"NCCN guidelines\u00ae insights: survivorship, version 2.2025: featured updates to the NCCN guidelines\u00ae","volume":"23","author":"Sanft","year":"2025","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"10.1016\/j.ecl.2026.07.002_bib4","doi-asserted-by":"crossref","first-page":"898.e1","DOI":"10.1016\/j.ajog.2020.06.039","article-title":"Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies","volume":"223","author":"Zhu","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"25","key":"10.1016\/j.ecl.2026.07.002_bib5","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.002_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017416","article-title":"Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN","volume":"10","author":"Thurston","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"10430","key":"10.1016\/j.ecl.2026.07.002_bib7","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0140-6736(23)02801-5","article-title":"Promoting good mental health over the menopause transition","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"issue":"10382","key":"10.1016\/j.ecl.2026.07.002_bib8","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2026.07.002_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.562275","article-title":"Menopause and brain health: hormonal changes are only part of the story","volume":"11","author":"Maki","year":"2020","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.002_bib10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajog.2024.10.054","article-title":"Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks","volume":"232","author":"Beste","year":"2025","journal-title":"Am J Obstet Gynecol"},{"issue":"19","key":"10.1016\/j.ecl.2026.07.002_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16193267","article-title":"Menopausal hormone therapy in breast cancer survivors","volume":"16","author":"Culhane","year":"2024","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ecl.2026.07.002_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/jwh.2018.27099.mensocrec","article-title":"Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations","volume":"28","author":"Maki","year":"2019","journal-title":"J. Womens Health"},{"issue":"9","key":"10.1016\/j.ecl.2026.07.002_bib13","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society","volume":"27","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.ecl.2026.07.002_bib14","article-title":"Role of estrogen receptors in health and disease","volume":"13","author":"Chen","year":"2022","journal-title":"Front Endocrinol"},{"issue":"31","key":"10.1016\/j.ecl.2026.07.002_bib15","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.01696","article-title":"Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO Clinical Practice Guideline","volume":"37","author":"Shapiro","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ecl.2026.07.002_bib16","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ecl.2026.07.002_bib17","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1210\/jc.2018-02339","article-title":"Higher insulin resistance and adiposity in postmenopausal women with breast cancer treated with aromatase inhibitors","volume":"104","author":"Gibb","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.002_bib18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2026.07.002_bib19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","article-title":"Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status","volume":"24","author":"Vehmanen","year":"2006","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ecl.2026.07.002_bib20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2026.07.002_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1448687","article-title":"Mechanisms of endocrine resistance in hormone receptor-positive breast cancer","volume":"14","author":"Gao","year":"2024","journal-title":"Front Oncol"},{"issue":"44","key":"10.1016\/j.ecl.2026.07.002_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1210\/endrev\/bnac017","article-title":"Estrogen receptor signaling in the immune system","volume":"12","author":"Chakraborty","year":"2023","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.002_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13058-023-01606-7","article-title":"Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment","volume":"25","author":"Hanamura","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"15","key":"10.1016\/j.ecl.2026.07.002_bib24","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1158\/1078-0432.CCR-19-0137","article-title":"Sex hormones and anticancer immunity","volume":"25","author":"\u00d6zdemir","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ecl.2026.07.002_bib25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/GME.0000000000002154","article-title":"The Women\u2019s Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context","volume":"30","author":"Chlebowski","year":"2023","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.002_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/PPO.0000000000000601","article-title":"Menopausal hormone therapy and breast cancer","volume":"28","author":"Chlebowski","year":"2022","journal-title":"Cancer J"},{"issue":"8","key":"10.1016\/j.ecl.2026.07.002_bib27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.2007.13.4338","article-title":"Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer","volume":"26","author":"Fournier","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.002_bib28","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ijc.20710","article-title":"Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort","volume":"114","author":"Fournier","year":"2005","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.002_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study","volume":"107","author":"Fournier","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ecl.2026.07.002_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13697137.2017.1421925","article-title":"The impact of micronized progesterone on breast cancer risk: a systematic review","volume":"21","author":"Stute","year":"2018","journal-title":"Climacteric"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.002_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13058-021-01425-8","article-title":"Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study","volume":"23","author":"Fornili","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.ecl.2026.07.002_bib32","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/JCO.2025.43.16_suppl.512","article-title":"The promise study: a presurgical randomized clinical trial of CE\/BZA vs placebo in postmenopausal women with ductal carcinoma in situ","volume":"43","author":"Kulkarni","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2026.07.002_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-022-06577-5","article-title":"Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen","volume":"193","author":"Bychkovsky","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"10.1016\/j.ecl.2026.07.002_bib35","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.002_bib36","article-title":"Hereditary breast and ovarian cancer syndrome","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ecl.2026.07.002_bib37","first-page":"djaf363","article-title":"Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2","author":"Kotsopoulos","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ecl.2026.07.002_bib38","series-title":"Genetic\/familial high-risk assessment: breast, ovarian, pancreatic, and prostate (Version 3.2026)","year":"2026"},{"issue":"9407","key":"10.1016\/j.ecl.2026.07.002_bib39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer\u2014is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ecl.2026.07.002_bib40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ecl.2026.07.002_bib41","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Menopausal hormone therapy after breast cancer: the Stockholm randomized trial","volume":"97","author":"Von Schoultz","year":"2005","journal-title":"JNCI Journal of the National Cancer Institute"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.002_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial","volume":"49","author":"Fahl\u00e9n","year":"2013","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2026.07.002_bib43","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10549-021-06436-9","article-title":"Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis","volume":"191","author":"Poggio","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ecl.2026.07.002_bib44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","article-title":"Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial","volume":"10","author":"Kenemans","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ecl.2026.07.002_bib45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.breast.2018.05.002","article-title":"The oncologic impact of hormone replacement therapy in premenopausal breast cancer survivors: a systematic review","volume":"40","author":"Wang","year":"2018","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.ecl.2026.07.002_bib46","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S1470-2045(25)00211-6","article-title":"Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the premenopausal breast cancer collaborative group","volume":"26","author":"O\u2019Brien","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2026.07.002_bib47","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2022.24140","article-title":"Management of menopausal symptoms: a review","volume":"329","author":"Crandall","year":"2023","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ecl.2026.07.002_bib48","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1210\/jc.2019-01603","article-title":"Global consensus position statement on the use of testosterone therapy for women","volume":"104","author":"Davis","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2026.07.002_bib49","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2213-8587(19)30189-5","article-title":"Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data","volume":"7","author":"Islam","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2026.07.002_bib50","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1176\/appi.ajp.2020.19080844","article-title":"Low-dose testosterone augmentation for antidepressant-resistant major depressive disorder in women: an 8-week randomized placebo-controlled study","volume":"177","author":"Dichtel","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.002_bib51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/AOG.0000000000006015","article-title":"Testosterone for the treatment of hypoactive sexual desire disorder in perimenopausal and postmenopausal women","volume":"146","author":"Kling","year":"2025","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.002_bib52","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S2213-8587(25)00394-8","article-title":"Menopausal hormone treatment and breast cancer","volume":"14","author":"Gompel","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2026.07.002_bib53","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1210\/jc.2014-2260","article-title":"Androgen therapy in women: a reappraisal: an endocrine society clinical practice guideline","volume":"99","author":"Wierman","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.002_bib54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/cancers9030021","article-title":"AR signaling in breast cancer","volume":"9","author":"Rahim","year":"2017","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ecl.2026.07.002_bib55","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1210\/me.2012-1107","article-title":"Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?","volume":"26","author":"Hickey","year":"2012","journal-title":"Mol Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2026.07.002_bib56","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41591-020-01168-7","article-title":"The androgen receptor is a tumor suppressor in estrogen receptor\u2013positive breast cancer","volume":"27","author":"Hickey","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ecl.2026.07.002_bib57","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fendo.2018.00594","article-title":"The divergent function of androgen receptor in breast cancer; analysis of steroid mediators and tumor intracrinology","volume":"9","author":"Bleach","year":"2018","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.002_bib58","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/AOG.0000000000005812","article-title":"Fezolinetant and elinzanetant therapy for menopausal women experiencing vasomotor symptoms: a systematic review and meta-analysis","volume":"145","author":"Menegaz de Almeida","year":"2025","journal-title":"Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.ecl.2026.07.002_bib59","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa2415566","article-title":"Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer","volume":"393","author":"Cardoso","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.002_bib61","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/j.clbc.2021.10.003","article-title":"Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review","volume":"22","author":"Bradbury","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"9488","key":"10.1016\/j.ecl.2026.07.002_bib62","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0140-6736(05)67215-7","article-title":"Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial","volume":"366","author":"Pandya","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ecl.2026.07.002_bib63","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/GME.0000000000002200","article-title":"The 2023 nonhormone therapy position statement of the North American Menopause Society","volume":"30","year":"2023","journal-title":"Menopause"},{"issue":"7","key":"10.1016\/j.ecl.2026.07.002_bib64","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamainternmed.2025.0990","article-title":"Nonhormonal treatment of menopausal vasomotor symptoms","volume":"185","author":"Huang","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.002_bib65","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/AOG.0000000000005288","article-title":"Nonestrogen therapies for treatment of genitourinary syndrome of menopause: a systematic review","volume":"142","author":"Casiano Evans","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ecl.2026.07.002_bib66","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10549-024-07564-8","article-title":"Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial","volume":"210","author":"Faltinov\u00e1","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.002_bib67","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/AOG.0000000000005294","article-title":"Safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast cancer","volume":"142","author":"Agrawal","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.002_bib68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/jamaoncol.2023.4508","article-title":"Vaginal estrogen therapy use and survival in females with breast cancer","volume":"10","author":"McVicker","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ecl.2026.07.002_bib69","doi-asserted-by":"crossref","DOI":"10.61622\/rbgo\/2025rbgo46","article-title":"Vaginal estrogen therapy for treatment of menopausal genitourinary syndrome among breast cancer survivors: a systematic review and meta-analysis","volume":"47","author":"Santos","year":"2025","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"7","key":"10.1016\/j.ecl.2026.07.002_bib70","first-page":"767","article-title":"\u201cThe 2022 Hormone Therapy Position Statement of The North American Menopause Society\u201d advisory panel. The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","year":"2022","journal-title":"Menopause"},{"issue":"10","key":"10.1016\/j.ecl.2026.07.002_bib71","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djac112","article-title":"Systemic or vaginal hormone therapy after early breast cancer: a danish observational cohort study","volume":"114","author":"Cold","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ecl.2026.07.002_bib72","first-page":"643","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"issue":"11","key":"10.1016\/j.ecl.2026.07.002_bib73","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1080\/14656566.2024.2391009","article-title":"Ospemifene and vulvovaginal atrophy: an update of the clinical profile for post-menopausal women","volume":"25","author":"Di Carlo","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.002_bib74","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jsxm.2021.12.010","article-title":"CO2-laser therapy and genitourinary syndrome of menopause: a systematic review and meta-analysis","volume":"19","author":"Filippini","year":"2022","journal-title":"J Sex Med"},{"issue":"14","key":"10.1016\/j.ecl.2026.07.002_bib75","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jama.2021.14892","article-title":"Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: a randomized clinical trial","volume":"326","author":"Li","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.002_bib76","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/GME.0000000000001416","article-title":"A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET trial","volume":"27","author":"Paraiso","year":"2020","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.ecl.2026.07.002_bib77","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/AOG.0000000000006081","article-title":"Platelet-rich plasma for genitourinary syndrome of menopause in breast cancer survivors","volume":"146","author":"Chen","year":"2025","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ecl.2026.07.002_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1590078","article-title":"Comparison of topical estrogen and platelet-rich plasma injections in the treatment of postmenopausal vaginal atrophy","volume":"12","author":"Atlihan","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.ecl.2026.07.002_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2025.108196","article-title":"Optimizing the regenerative potential of vaginal fibroblasts: the role of autologous platelet-rich plasma and hyaluronic acid in vitro","volume":"194","author":"Berndt","year":"2025","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.002_bib80","doi-asserted-by":"crossref","DOI":"10.1093\/jsxmed\/qdaf307","article-title":"Platelet-rich plasma in the management of vulvovaginal disorders: a systematic review","volume":"23","author":"De Ponte","year":"2026","journal-title":"J Sex Med"},{"issue":"13","key":"10.1016\/j.ecl.2026.07.002_bib81","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00266-023-03844-8","article-title":"Exosomes in the real world of medical aesthetics: a review","volume":"48","author":"Pinto","year":"2024","journal-title":"Aesth Plast Surg"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.002_bib82","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13058-024-01886-7","article-title":"Safety and efficacy of topical testosterone in breast cancer patients receiving ovarian suppression and aromatase inhibitor therapy","volume":"26","author":"Taranto","year":"2024","journal-title":"Breast Cancer Res"},{"issue":"7","key":"10.1016\/j.ecl.2026.07.002_bib83","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaoncol.2025.1138","article-title":"Breast cancer outcomes in transgender and gender-diverse patients in the national cancer database","volume":"11","author":"Chan","year":"2025","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.ecl.2026.07.002_bib84","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.3390\/cancers17244022","article-title":"Insomnia in women surviving breast and gynecological cancers\u2014a narrative review to address the hormonal factor","volume":"17","author":"Martella","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.002_bib85","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41523-022-00414-0","article-title":"Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation","volume":"8","author":"Smith","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.002_bib86","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/s12885-023-11122-8","article-title":"Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review","volume":"23","author":"Eliassen","year":"2023","journal-title":"BMC Cancer"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:41:09Z","timestamp":1792593669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0889852926000587"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.07.002","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormone Therapy Considerations for Breast Cancer Survivors and High-Risk Women","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}